Acambis plc
We represented Acambis plc, a leading vaccine development company listed on the London Stock Exchange, on the £276 million recommended takeover offer by Sanofi-Aventis. This transaction was one of the largest European pharmaceutical deals announced in 2008, per Mergerstat's 2008 year end release.
|
Catalyst Biosciences, Inc.
We represented Catalyst Biosciences, a pioneer in the discovery and development of engineered proteases known as Alterase™ therapeutics, in its $40.4 million Series C financing round. New investor Essex Woodlands Health Ventures led the round, with participation from existing investors Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures and Sofinnova Ventures. The deal was among the top 15 venture capital deals of 2008, according to FierceBiotech.
|
MediGuide Inc.
We represented MediGuide Inc., a privately owned Israeli medical device company based in Haifa, in its $300 million acquisition by St. Jude Medical, the $10 billion New York Stock Exchange producer of cardiovascular medical devices.
|
Mentor Corporation
We advised Mentor Corporation (NYSE: MNT), a market leader and supplier of medical products for the global aesthetic market (e.g., silicone breast implants and liposuction products), in its acquisition by Johnson & Johnson (NYSE: JNJ) through a $1.07 billion cash tender offer ($1.12 billion including debt) announced December 1, 2008. Mentor is expected to operate as a stand-alone business unit reporting through ETHICON, Inc., a Johnson & Johnson company and leading provider of suture, mesh and other products for a wide range of surgical procedures. The transaction is one of only two $1B+ deals announced in Q4 2008 and was among the largest life sciences deals announced for the year.
|
S*BIO Pte Ltd
We advised Singapore-based S*BIO on a $550 million development collaboration and option and license agreement with Onyx Pharmaceuticals, Inc., to develop and commercialize S*BIO's novel JAK2 inhibitors SB1518 and SB1578 in North American and European markets.
|
Elan Pharma International Limited v. Abraxis Bioscience
(Distrcit of Delaware). Represented Abraxis BioScience in defending its lead product, Abraxane, against claims by Elan Pharmaceutical of infringing Elan’s patents for coated nanoparticles used to deliver paclitaxel for the treatment of metastatic breast cancer. This was the first nanotechnology patent case taken to jury trial. The case settled in 2011.
|